News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zeria Pharmaceutical Co., Ltd. Announces the Results From Phase III, Double-Blind, Placebo-Controlled Study of Z-338 for Functional Dyspepsia Conducted in Japan



6/28/2010 12:03:01 PM

TOKYO--(BUSINESS WIRE)--Zeria Pharmaceutical (TOKYO:4559) (ISIN: JP3428850006) announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; “acotiamide”) for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract. Z-338 was developed by Zeria Pharmaceutical Co., Ltd based in Tokyo, and is currently being co-developed by Astellas Pharma Inc based in Tokyo. Acotiamide is expected to be the first-in-class for FD diagnosed by the Rome ?, and will be launched in Japan ahead of the rest of the world.

Read at BioSpace.com


comments powered by Disqus
   
Nausea

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES